2,192 research outputs found
Maxillary Sinus Osteoma as a Support for Dental Implant Associated to Sinus Augmentation Procedure: A Case Report and Literature Review
No full textBackground: Maxillary sinus augmentation is a method extensively used to restore sufficient bone volume in the posterior maxilla to allow for the placement of fixtures. The purpose of the present case report was to describe a rare case of sinus osteoma used for implant support and to review the relevant literature. Materials and Methods: A 58-year-old man with a radiopaque intrasinusal lesion was referred for rehabilitation of the maxilla. The lesion was probably an osteoma and involved the nasal wall of the maxillary sinus. After discussing the options with the patient, he agreed to maintain the lesion and a sinus augmentation with a bone graft. A part of the osteoma was partially removed for histological analysis while avoiding perforation or tearing of the schneiderian membrane. After six months, 6 implants (Bone System Implant, Milano, Italy) were placed in the maxilla, two of which were inserted in the osteoma. Results: The two implants placed in the osteoma were perfectly osseointegrated. The graft material appeared well-integrated with no local signs of inflammation. No postoperative events or symptoms were reported after the surgery stages and at a 6-month follow-up. Regarding the two implants placed in the osteoma: article selection identified 9 case reports, 2 case series, and 1 retrospective study for a total of 58 subjects, 35 males and 25 females. The patients’ ages were heterogeneous and ranged between 12 and 79 years old. Conclusions: In the present case, we decided to leave the osteoma because it was asymptomatic and used as dental implant support. The effectiveness of the present investigation can provide useful guidance for surgeons and dentists in the management of similar clinical situations. © 2022 by the authors. Licensee MDPI, Basel, Switzerland
Introduction: Perspectives on Post-Truth
No full textThis opening piece of the collection 'Perspectives on Post-Truth' aims to accomplish three tasks. First, and foremost, it highlights the issue’s distinctive feature, namely its variegated approach to post-truth. The leading idea in assembling it has been to draw on different methodologies, theoretical approaches, and competences, in order to gain a finegrained understanding of the post-truth condition and to develop an effective toolkit to address the most pressing challenges it poses to our societies. The underlying conviction is that a variegated approach is required by the multifaceted nature of the post-truth condition. The curious reader willing to venture through the issue will thus be exposed to different perspectives on post-truth: some pieces address it from a traditional epistemological perspective, others explore post-truth from the perspective of social epistemology, and still others adopt a semiotic perspective. In light of this multiplicity of perspectives, the second task of this piece has been to provide a brief thematic overview of the key issues and perspectives in order to illustrate the overall narrative of the project. The third and final task has been to give a detailed synopsis of each
contribution so that the reader will know precisely what to expect from it
SATISFACTION GRADE ASSESSMENT OF PATIENTS TREATED WITH ZYGOMATIC IMPLANTS WITH SELF-TAPPING APEX AND MACHINED BODY
No full text
FISH testing of HER2 IHC 1+ early breast cancer with unfavorable prognostic factors
No full textF. Giotta2, S. Petroni 1, L. Caldarola 1, A. Latorre 2, R. Mallamaci 3, V. Lorusso 2, M. Zambetti 1, G. Simone 1
1 Pathology Department, NCRC Istituto Tumori “Giovanni Paolo II”, Bari, Italy
2 Medical Oncology Unit, NCRC Istituto Tumori “Giovanni Paolo II”, Bari, Italy
3 Human Physiology Institute, University of Bari, Italy
FISH testing of HER2 IHC 1+ early breast cancer with unfavorable prognostic factors
Background HER2-positive tumors are associated with a poor prognosis and a shortened disease-free and overall survival as well as with other unfavorable prognostic tumor characteristics (high histological grade, high proliferative index, negative or low estrogen receptor expression, etc.). HER2-positive tumors are also responsive to treatment with trastuzumab in reducing the risk of recurrence and improving survival. The aim of this study is to assess the incidence of HER2 gene amplification in selected tumors with adverse prognostic features which scored 1+ by immunohistochemistry (IHC).
Methods 75 women with infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC) scoring 1+ by IHC were included. Forty-eight invasive breast carcinoma samples were selected according to unfavorable prognostic tumor characteristics and tested by FISH. HER2 amplification was evaluated using Vysis HER2/Cep17 probe (Path Vysion HER2 DNA Probe Kit®, Abbott Molecular, IL); ratio–based amplification was considered present when the HER2/Cep17 ratio was 2 or more and copy number-based amplification was considered present when the mean HER2 copy number was more than 6, in agreement with the ASCO/CAP/SIAPEC guidelines.
Results In 2013, 331 patients with invasive breast tumors were tested by IHC; 75 cases (23%) were scored 1+ of which 62 cases (19%) of IDC and 13 cases (4%) of ILC. Forty-eight invasive breast carcinoma samples (64%) were selected according to one or more unfavorable prognostic tumor characteristics; 22 out of 48 tumors (46%) showed high histological grade (G3); 27 cases (56%) had high proliferative index (Ki-67≥30%); 32 tumor samples (67%) were node-positive; and 29 cases (60%) showed vascular invasion. FISH was performed on 28 of the 1+ patients with adverse tumor characteristics and 6 IDC out of 48 (12.5%) showed HER2 amplification.
Conclusions Our preliminary retrospective data suggest that 6 patients out of 48 (12.5%) scoring 1+ by IHC show HER2 amplification, in agreement with the most recently published literature data. In order to not deny the benefit deriving from trastuzumab administration, in breast cancer patients showing IHC 1+, it is advisable to test HER2 gene amplification by FISH
Increased cyclooxygenase-2 expression is associated with better clinical outcome in patients submitted to complete ablation for severe endometriosis
No full textRole of the substrates and deposition parameters on the photoluminescence spectra of C60 films
No full textSafety and effectiveness of human papillomavirus (HPV) vaccination: NCI of Milan position statement
No full textFindings linking mismatch repair mutation with age at endometrial and ovarian cancer onset in Lynch syndrome
No full text
- …
